Baxter Announces Collaboration with Chatham Therapeutics for Factor IX
Baxter International Inc. (NYSE: BAX) today announced that it has entered into an exclusive global agreement with Chatham Therapeutics, LLC, an affiliate of Asklepios BioPharmaceutical, Inc. (AskBio), for the development and commercialization of potential treatments for hemophilia B utilizing Chatham's gene therapy technology.
The collaboration will allow Baxter to investigate Chatham's Biological Nano Particles^TM (BNP), an advanced recombinant adeno-associated virus-(rAAV) based gene therapy technology that has shown potential therapeutic benefit in early clinical studies. A small independent study involving six patients using Chatham technology components was the topic of a 2011 article in The New
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.